ABLIVA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.172 SEK | +1.18% |
|
+1.78% | -29.94% |
| 02-23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
Business Summary
Number of employees: 8
Sales per Business
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Mitochondrial Diseases
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Sales per region
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Sweden
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 02/02/21 |
Eskil Elmér
FOU | Founder | 54 | 31/01/00 |
| Director of Finance/CFO | 57 | 30/11/13 | |
Dag Nesse
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/23 |
Magnus Hansson
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/12/07 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 27/04/16 | |
David Bejker
BRD | Director/Board Member | 49 | 26/04/17 |
Eskil Elmér
FOU | Founder | 54 | 31/01/00 |
Roger Franklin
BRD | Director/Board Member | 45 | 19/05/20 |
Denise Goode
BRD | Director/Board Member | 66 | 26/04/18 |
| Director/Board Member | 64 | 26/04/17 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 1,056,299,165 | 930,212,762 ( 88.06 %) | 0 | 88.06 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.94% | 20.99M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.48% | 22.18B | |
| -16.67% | 21.2B | |
| -9.58% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- ABLI Stock
- Company Abliva AB
